A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2015
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms PHACS
- 10 Jun 2017 Biomarkers information updated
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 98).
- 09 Oct 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.